You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Southeast Xlerator Network

    SBC: XLERATEHEALTH, LLC            Topic: R

    The Southeast XLerator Network proposes to create a networked and easily accessible regional technology transfer accelerator hub (“XLerator Hub” or “Hub”) to share best practices, disseminate education content, and offer products, services, facilities and other resources connected through both physical and online platforms for innovators and trainees in the Southeast IDeA states. Led by XL ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Naloxone Nasal Spray Development

    SBC: ANTIOP, INC.            Topic: NIDA

    DESCRIPTION: The following proposal is a follow-on Phase 2 b application from our initial proposal (1-R42 DA 030001). U.S. drug overdose deaths, mostly commonly from opioids, now exceed deaths from automobile accidents. There is a significant unmet medical need to provide additional pharmacologic options for treatment of opioid overdose. Emergency medical service personnel would prefer a non- inj ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Project Summary Bacillus anthracis (Ba) is a Gram-positive spore forming bacterium that is listed as an agent of highest concern (Category A) by NIAID and CDC. Ba is easy to grow, and its spores can be formulated into highly stable powder form and disseminated as aerosol or used to contaminate food or water. In 2001, letters laced with powdered anthrax spores were mailed to several US politicians. ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Lentiviral-MGMT gene transfer into hematopoietic stem cells

    SBC: LENTIGEN CORPORATION            Topic: NCI

    DESCRIPTION (provided by applicant): Therapeutic stem cell gene transfer relies on long-term gene expression achieved by integration of new DNA into the cellular genome. Current clinical trials featuring oncoretroviruses have encountered a number of roadblocks that include low levels of gene transfer, poor expression, and a recognized preferential insertion near promoter regions that increases the ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. HUCBC modulation of Alzheimer's-like pathology and behavioral changes

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): In the past years, we have shown that human umbilical cord blood cells (HUCBC, U-CORD- CELL ) provide cognitive recovery in animal models of neurodegenerative disease. Infusion of HUCBC resulted in reduced infarct volume as well as in rescue of behavioral benefits in an animal model of stroke. We further showed that HUCBC infusion proved to be beneficial in ani ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. A Home Exercise Program (DVD) for Women with Infants and Young Children

    SBC: KLEIN BUENDEL, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Becoming a mother is a significant transition in a woman's life. This transition can precipitate major changes in health behaviors, like physical activity. Once a woman has a child she is much less likely to participate in regular, moderate to vigorous physical activity compared to women without children. Thus, new mothers are at risk for future weight gain and ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Microfluidic CAR-T Cell Processing Device

    SBC: GPB Scientific, Inc.            Topic: 101

    ABSTRACT The goal of this Fast-Track STTR project is to develop a Deterministic Lateral Displacement (DLD) microfluidic device that can enrich white blood cells (WBCs) from a typical leukapheresis unit in 1 hr, for use in manufacturing cancer cellular immunotherapy. Chimeric antigen receptor T cell (CAR-T) therapy has been recommended for FDA approval to treat relapsed or refractory pediatric and ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    Type 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Clinical validation and commercialization of a novel hydrogel-based vaginal packing system for pelvic brachytherapy

    SBC: BrachyFoam, LLC            Topic: 102

    This proposal aims to complete preclinical validation and commercialize a novel vaginal packing product based upon a biocompatible polymer hydrogel strategy. The hydrogel will form in situ after being injected into a bag placed within the vaginal cavity during pelvic brachytherapy. The hydrogel packing can then be removed readily after the brachytherapy treatment. This Phase II proposal focuses on ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government